Most teams start the search for a freeze-drying partner by asking how many lyophilizers a facility has and what it costs per batch. Those are reasonable questions. They are also the two that predict the least about how the project will actually go.
The projects that go badly rarely fail because a freeze-dryer was too small. They fail because a cycle was designed by trial and error rather than from thermal data, because nobody measured collapse temperature before committing to a shelf ramp, because the analytical work that would have caught a moisture drift was outsourced to a third lab with a three-week turnaround, or because the pilot process could never have run at full chamber load in the first place. By the time any of that surfaces, you have usually burned six to twelve months and a batch of expensive material.
This guide covers what to evaluate instead, what good answers sound like, and the specific questions that separate a genuine contract lyophilization partner from a facility that simply owns freeze-dryers.
The short answer
Choose a contract freeze-drying partner on scientific depth first, quality system second, capacity third. Confirm the provider measures the thermal properties of your formulation and will share the raw data; that formulation development, cycle design, analytical testing, and scale-up sit under one roof and one quality system; that the certifications cover the specific line your product will run on; and that there is a documented path from feasibility batch to validated commercial production without a mid-programme site transfer. Price and freeze-dryer count matter, but they are tiebreakers, not selection criteria.
What a contract freeze-drying partner should actually be doing
Freeze-drying is not a single service. A capable partner runs a connected pathway, and it is worth knowing which stages a prospective provider covers before the first call:
| Stage | What happens | Why teams underestimate it |
|---|---|---|
| Feasibility | Small-scale trial to confirm the product survives sublimation at all | Often skipped to save time; catches fatal formulation issues cheaply |
| Thermal characterization | Measuring glass transition of the freeze-concentrate (Tg′), eutectic and collapse temperature | This is the data the entire cycle is designed around |
| Formulation development | Screening cryoprotectants, lyoprotectants, bulking agents, buffers | A poor formulation cannot be rescued by a clever cycle |
| Cycle development | Freezing profile, primary drying shelf temperature and chamber pressure, secondary drying | Cycles copied from a similar product are the most common source of failure |
| Analytical testing | Residual moisture, reconstitution, cake appearance, potency or activity, stability | Turnaround time here governs the whole development timeline |
| Scale-up | Moving from a few trays to a full chamber load | Heat transfer at the shelf edge behaves nothing like the centre |
| Validation and commercial supply | Process validation batches, release testing, ongoing production | Where an underspecified quality system finally bites |
If a provider covers only the back half of that list — filling and drying to your instructions — you are not outsourcing lyophilization. You are renting a freeze-dryer and keeping all the technical risk.
Nine things to evaluate before you sign
1. Scientific depth, before the equipment list
The single most useful diagnostic question you can ask is: how do you determine collapse temperature, and will you send us the raw data?
A partner with real capability will answer specifically. They will talk about differential scanning calorimetry for Tg′ and eutectic behaviour, freeze-dry microscopy for direct observation of collapse, and how the two sometimes disagree. They will explain why they hold primary drying product temperature a few degrees below collapse rather than at it. They will offer the thermograms without being asked twice.
A weaker provider will say they "have a lot of experience with formulations like yours" and propose a standard cycle. That is the answer to listen for. Experience is valuable, but a cycle built on analogy rather than measurement is a cycle that works until your formulation is slightly different from the analogy — which it always is.
2. Whether they will challenge your formulation
There is a meaningful difference between a provider who runs what you hand them and one who tells you the formulation will not lyophilize well and proposes changes.
The second kind is more useful and occasionally more uncomfortable. Sucrose versus trehalose, the ratio of stabilizer to active, whether a bulking agent is needed to produce an elegant cake, whether a surfactant is preventing interfacial denaturation during freezing — these choices determine whether you end up with a robust product or one that passes release and fails at month nine of stability.
Ask directly: will you propose formulation changes, or only process changes? If the answer is only process, understand that you are retaining the formulation risk.
3. Format fit: vials, beads, cakes, bulk
Format is a strategic decision, not a packaging detail, and it should be settled early because it changes the entire development path.
Vials remain the default for injectables and many reagents, and the surrounding infrastructure — stoppers, crimps, container closure integrity testing — is mature and well understood.
Unit-dose lyophilized beads have reshaped molecular diagnostics. Each bead holds a complete single reaction: polymerase, primers, probes, buffers and stabilizers, measured at manufacture. The end user adds sample and water. There is no master mix to pipette, no partially used vial, and beads drop into cartridges, strips and microfluidic consumables without redesigning the reagent. For anything heading toward point-of-care or decentralized testing, unit-dose is usually the right answer.
Bulk cakes in trays suit intermediates and material that will be milled or blended downstream.
Not every provider does all three well. A facility built around sterile vial fill-finish may treat bead production as a side line, and vice versa. Match the format to the product, then find a partner whose core competence is that format — rather than choosing a partner and letting their equipment decide your product architecture.
4. A quality system that matches your regulatory path — on your line
This is where vague answers cost the most, because "we're certified" is not an answer.
An in vitro diagnostic heading for Health Canada, FDA 510(k) or IVDR needs a partner working under ISO 13485, with design control and traceability that will survive a notified body or agency review. A sterile injectable needs cGMP, and if it is going to the EU, an understanding of EU GMP Annex 1 contamination control expectations. Research-use-only reagents may need considerably less, and paying for GMP you do not need is a real cost.
The question that matters is narrower than the certification itself: which certifications cover the specific line and suite our product would run on, and when was that scope last audited? Multi-site organizations frequently hold certifications that apply to one facility and not another. Ask to see the certificate scope, the most recent audit outcome, and any open findings.
Ask also about the quality agreement: deviation handling, change control, CAPA, your audit rights, and who signs off on a cycle change once the process is locked.
5. Which analytical tests are in-house
Development speed is largely a function of feedback speed. A provider who runs residual moisture by Karl Fischer, cake appearance, reconstitution time, and product-specific activity assays in their own lab can iterate a cycle in days. A provider who ships samples to a contract lab adds one to three weeks to every iteration, and those weeks compound across a development programme.
Get a specific list: what is in-house, what is outsourced, what the turnaround is for each, and whether stability storage is on site. Analytical capability is usually the difference between a six-month and a fourteen-month development timeline, and it almost never appears in a price comparison.
6. The scale-up path, and whether it involves moving buildings
Lyophilization does not scale linearly. Vials at the edge of a shelf receive radiant heat from the chamber wall and dry faster than vials in the centre. At small load, that edge effect is a curiosity. At full load in a production chamber, it is the reason half your batch is over-dried and the other half is not dry enough.
Two questions:
How is shelf-position uniformity mapped and documented at full chamber load? You want to hear about thermocouple placement, a mapping study, and documented acceptance criteria — not an assurance that it is fine.
Does scale-up happen on this site? A provider running development, pilot and commercial lyophilizers under one roof and one quality system can scale without a formal technology transfer. A provider who develops in one place and manufactures in another has built a transfer into your programme, with all the comparability work, revalidation and schedule risk that carries.
7. Technology transfer and documentation discipline
Whether material is coming to them or may one day leave, the quality of the paper trail determines what the process is worth.
Ask what you receive at the end of development. A strong answer includes a development history report explaining the rationale for every critical process parameter, not just the final recipe. That distinction matters enormously later: a recipe tells a future site what to do, while a rationale tells them what they may safely change.
Confirm in writing who owns the cycle, the formulation, the analytical methods and the data. Some agreements quietly leave developed process IP with the provider, which turns a supplier relationship into a dependency.
8. Capacity honesty and single-site risk
Ask for current slot availability in weeks, not a reassurance about capacity. Ask what happens if a lyophilizer goes down mid-campaign, whether there is a second unit of equivalent scale, and what the realistic recovery is.
Single-site providers are not disqualified by this. Many of the best specialist lyophilization operations run from one facility, and that concentration is exactly what gives them their process knowledge. But you should price the risk consciously, and for commercial supply of a critical product, you should know what your contingency is.
9. How they communicate when something goes wrong
Every freeze-drying programme has a bad batch. Cakes collapse, moisture drifts, activity drops at an accelerated stability timepoint. What varies is what happens next.
Ask for an example. Tell me about a project where the first cycle did not work. What did you do? You are listening for a diagnostic sequence — what they measured, what hypothesis they formed, how they tested it — and for whether the client heard about it in week one or week six. The answer tells you more about a prospective partner than any capability slide.
Red flags
- A cycle proposed before any thermal characterization has been run on your formulation
- Reluctance to share raw data — thermograms, product temperature traces, chamber pressure logs
- Certification claims that cannot be tied to a specific line, suite or scope
- No documented shelf-position uniformity mapping at full load
- Development and commercial manufacturing at different sites, presented as a non-issue
- Quoted timelines with no stated assumptions about material supply or analytical turnaround
- An agreement that leaves process IP or analytical method ownership ambiguous
- Pricing far below the field, which usually means development work has been quietly moved out of scope
Questions to ask on the first call
- How do you determine collapse temperature, and will you share the raw data?
- Will you propose formulation changes, or only run what we provide?
- Which analytical tests are in-house, and what is the turnaround on each?
- How is shelf-position uniformity mapped and documented at full chamber load?
- Which quality certifications cover the specific line our product would run on?
- Does development, pilot and commercial production happen at this site?
- What is the realistic timeline, in weeks, from feasibility batch to validated production?
- What do we receive at the end of development, and who owns it?
- What is your current slot availability, and what is the contingency if equipment goes down?
- Tell us about a project where the first cycle failed.
A simple scoring framework
Weighted scoring beats impressions, particularly when several people are involved in the decision. A workable starting point:
| Criterion | Weight | What a strong answer looks like |
|---|---|---|
| Scientific and formulation capability | 25% | Measures thermal properties, shares data, proposes formulation changes |
| Quality system fit | 20% | Certification scope covers your line and your regulatory path |
| Analytical capability in-house | 15% | Moisture, activity, reconstitution, stability on site with short turnaround |
| Scale-up path | 15% | Development through commercial on one site, uniformity mapped at full load |
| Format expertise | 10% | Core competence in your format, not a side line |
| Capacity and timeline realism | 10% | Slot availability in weeks, stated assumptions, contingency plan |
| Commercial terms and IP clarity | 5% | Explicit ownership of cycle, methods and data |
Adjust the weights to your situation. A commercial-stage product weights quality and capacity more heavily; an early-stage diagnostic weights formulation science and analytical speed.
Geography is a real variable
Where the facility sits affects more than shipping cost.
Frozen or temperature-sensitive material crossing a border adds customs holds, cold-chain handoffs, and excursion risk to every single development iteration, not just commercial shipments. Domestic manufacturing capacity has also become a procurement and policy consideration for diagnostics and biotech companies in a way it simply was not a decade ago, particularly for organizations supplying public health systems or applying for regional funding.
There is a practical dimension too. Being able to attend a cycle run, stand in front of the chamber, and look at the cakes coming out is worth more than most people expect. Development goes faster when the client can be in the room.
Realistic timelines
Timelines vary enormously with formulation complexity and regulatory path, but as a planning guide:
- Feasibility batch: a few weeks from material receipt
- Thermal characterization and formulation screening: several weeks, in parallel where possible
- Cycle development and optimization: typically the longest development phase, driven by analytical turnaround
- Pilot and scale-up: weeks to a few months, considerably longer if a site transfer is involved
- Process validation to commercial release: months, dependent on stability requirements and regulatory pathway
Any provider quoting firm dates before seeing your formulation is quoting a sales number. A provider who gives ranges with stated assumptions — material availability, analytical turnaround, number of cycle iterations budgeted — is giving you something you can plan against.
Frequently asked questions
What is the difference between freeze-drying and lyophilization?
None. They are the same process under different names. Freeze-drying is the plain-language term; lyophilization is the technical term used in pharmaceutical and diagnostics manufacturing. Both describe removing water by freezing a product and converting the ice directly to vapour under vacuum, bypassing the liquid phase.
Is it cheaper to bring lyophilization in-house?
Below a fairly high utilization threshold, no. The freeze-dryer is the smaller part of the cost. A controlled fill environment, validated utilities, qualification, calibration, cleaning and maintenance programmes, and staff experienced enough to recognize a marginal cycle all cost more than the equipment, and they cost the same whether the chamber runs twelve times a year or two hundred. Outsourcing converts a fixed capital burden into a variable cost and buys process knowledge that takes years to build internally.
How many contract freeze-drying providers should we evaluate?
Three is usually right. Two gives you no calibration on what a good answer sounds like; more than four and the evaluation itself becomes the bottleneck. Screen more widely on paper, then take three to a technical deep dive.
Should we choose vials or lyophilized beads?
It depends on the end user. Vials suit injectables and laboratory reagents where a technician will reconstitute a known volume. Unit-dose beads suit decentralized and point-of-care testing, where each bead carries one complete pre-measured reaction and integrates directly into cartridges and consumables. Settle this before cycle development starts, because the two paths diverge early.
What certifications should a contract lyophilization partner hold?
It depends entirely on your product's regulatory path. ISO 13485 for in vitro diagnostics and medical devices; cGMP for pharmaceutical products, with EU GMP Annex 1 relevant for sterile products supplied into Europe. The important check is that the certification scope covers the specific line your product will run on, not simply the organization as a whole.
What data should we receive at the end of development?
Thermal characterization data including thermograms, product temperature and chamber pressure traces for development runs, the final cycle recipe, analytical results, and — most importantly — a development history report explaining why each critical process parameter was set where it was. The rationale is what makes the process transferable and defensible in a regulatory filing.
How long does lyophilization cycle development take?
Commonly several months, and the pace is usually set by analytical turnaround rather than chamber time. Each cycle iteration requires testing before the next design decision, so a partner with in-house residual moisture and activity testing can compress a development programme substantially compared with one that outsources analysis.
Where Lyovial fits
Lyovial provides contract lyophilization services in Canada, running the full pathway from a single facility: feasibility work, thermal characterization, formulation development, cycle optimization, unit-dose bead manufacturing, analytical testing and validated commercial production, under one quality system.
The practical consequence of that structure is the one covered in section six above: there is no mid-programme site transfer between development and manufacturing, and the team that characterized your formulation is the team that runs the validation batches.
If you are working through the evaluation questions in this guide, we are happy to answer them directly — including the ones about raw data and certification scope. Get in touch or read more about our facility and capabilities.